Related Experiment Video
Updated: Jul 11, 2026
09:43
Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts
Published on: August 1, 2025
[The fibroblast growth factor as a predictor of symptomatic change under combined pharmacological treatment of benign
Georgian Medical News
|October 9, 2007
Abstract:
The results of our study showed, that long-term combined medical treatment of benign prostatic hyperplasia (Finasteride 5 mg/day + Tamsulosin 0.4 mg/day) significantly decreases values of IPSS and residual urine volume (RUV) in patients, which basic level of bFGF in serum does not exceed 5.9 pg/ml. On the other hand pharmacological treatment was insufficient in patients with bFGF basic level equal or more than 5.9 pg/ml; values of IPSS and RUV did not decrease.